{
    "ticker": "ACAD",
    "name": "ACADIA Pharmaceuticals Inc.",
    "description": "ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. Founded in 1993 and headquartered in San Diego, California, ACADIA is best known for its lead product, NUPLAZID (pimavanserin), which is approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company's mission is to improve the lives of patients through the advancement of novel therapeutic options, particularly for patients suffering from serious neuropsychiatric disorders. ACADIA is committed to conducting rigorous clinical trials and has a robust pipeline that includes additional programs targeting schizophrenia and other neurodegenerative diseases. The company strives to leverage its expertise in neuroscience to develop transformative therapies that can make a significant impact in the field. With a strong commitment to research and development, ACADIA continues to explore new pathways and mechanisms of action that could lead to breakthroughs in the treatment of complex neurological conditions.",
    "industry": [
        "Pharmaceuticals",
        "Biotechnology"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "1993",
    "website": "https://www.acadia-pharm.com",
    "ceo": "Steve Davis",
    "social_media": {
        "twitter": "https://twitter.com/ACADIAPharma",
        "linkedin": "https://www.linkedin.com/company/acadia-pharmaceuticals/"
    },
    "investor_relations": "https://investors.acadia-pharm.com",
    "key_executives": [
        {
            "name": "Steve Davis",
            "position": "CEO"
        },
        {
            "name": "Eric A. E. K. D. K. G. L. A. B. K. L. M. C. M. D. A.",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Approved Products",
            "products": [
                "NUPLAZID"
            ]
        },
        {
            "category": "Pipeline Products",
            "products": [
                "Pimavanserin for Schizophrenia",
                "Other CNS Disorders"
            ]
        }
    ],
    "seo": {
        "meta_title": "ACADIA Pharmaceuticals Inc. | Innovative CNS Therapies",
        "meta_description": "Explore ACADIA Pharmaceuticals Inc., a leader in CNS drug development, known for NUPLAZID, and dedicated to improving the lives of patients with serious neuropsychiatric disorders.",
        "keywords": [
            "ACADIA",
            "NUPLAZID",
            "CNS Disorders",
            "Biopharmaceuticals",
            "Parkinson's Disease",
            "Neuropsychiatry"
        ]
    },
    "faq": [
        {
            "question": "What is ACADIA Pharmaceuticals known for?",
            "answer": "ACADIA Pharmaceuticals is known for developing NUPLAZID, a treatment for Parkinson's disease psychosis."
        },
        {
            "question": "Who is the CEO of ACADIA Pharmaceuticals?",
            "answer": "Steve Davis is the CEO of ACADIA Pharmaceuticals Inc."
        },
        {
            "question": "Where is ACADIA headquartered?",
            "answer": "ACADIA is headquartered in San Diego, California, USA."
        },
        {
            "question": "What are ACADIA's main products?",
            "answer": "ACADIA's main product is NUPLAZID, with additional therapies in its pipeline targeting schizophrenia and other CNS disorders."
        },
        {
            "question": "When was ACADIA founded?",
            "answer": "ACADIA was founded in 1993."
        }
    ],
    "competitors": [
        "SAGE",
        "BIIB",
        "VRTX",
        "PTCT"
    ],
    "related_stocks": [
        "JNJ",
        "PFE",
        "MRK",
        "AMGN"
    ]
}